NASDAQ:ENTX Entera Bio (ENTX) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free ENTX Stock Alerts $1.67 +0.13 (+8.44%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.54▼$1.7550-Day Range$0.74▼$1.7252-Week Range$0.52▼$1.87Volume124,619 shsAverage Volume138,205 shsMarket Capitalization$48.10 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSocial Media Get Entera Bio alerts: Email Address Entera Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside498.8% Upside$10.00 Price TargetShort InterestHealthy0.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.02Based on 4 Articles This WeekInsider TradingAcquiring Shares$15,269 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.02 out of 5 starsMedical Sector617th out of 938 stocksBiological Products, Except Diagnostic Industry100th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Entera Bio has a forecasted upside of 498.8% from its current price of $1.67.Amount of Analyst CoverageEntera Bio has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.03% of the outstanding shares of Entera Bio have been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently increased by 523.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENTX. Previous Next 2.8 News and Social Media Coverage News SentimentEntera Bio has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Entera Bio this week, compared to 0 articles on an average week.Search Interest9 people have searched for ENTX on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows2 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,269.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.90% of the stock of Entera Bio is held by insiders.Percentage Held by InstitutionsOnly 14.11% of the stock of Entera Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Entera Bio Stock (NASDAQ:ENTX)Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Read More ENTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTX Stock News HeadlinesMarch 26, 2024 | globenewswire.comEntera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsMarch 23, 2024 | finance.yahoo.comWe Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business GrowthMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 20, 2024 | globenewswire.comEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeMarch 12, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 9, 2024 | finance.yahoo.comENTX May 2024 5.000 callMarch 8, 2024 | globenewswire.comEntera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | investing.comEntera Bio regains NASDAQ compliance with bid priceMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 4, 2024 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 4, 2024 | globenewswire.comEntera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 17, 2024 | finance.yahoo.comENTX Mar 2024 2.500 callJanuary 30, 2024 | finance.yahoo.comEntera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 20, 2024 | ca.finance.yahoo.comENTX Jan 2024 10.000 callJanuary 3, 2024 | finance.yahoo.comEntera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleDecember 31, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Short Interest ReportDecember 27, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX) Dividends: History, Yield and DatesDecember 26, 2023 | benzinga.comEntera Bio Stock (NASDAQ:ENTX), Analyst Ratings, Price Targets, PredictionsDecember 26, 2023 | finance.yahoo.comEntera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025November 29, 2023 | finance.yahoo.comInterim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide PlatformNovember 27, 2023 | msn.comEntera Bio (ENTX) Price Target Increased by 66.67% to 10.20November 14, 2023 | baystreet.caEntera Bio Flat on Release of Q3 NumbersNovember 14, 2023 | msn.comEntera Bio GAAP EPS of -$0.08November 14, 2023 | finance.yahoo.comEntera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in DevelopmentNovember 11, 2023 | morningstar.comEntera Bio Ltd ENTXNovember 9, 2023 | finance.yahoo.comEntera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for OsteoporosisOctober 16, 2023 | finance.yahoo.comEntera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual MeetingSee More Headlines Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/28/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+498.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax Margin-71,042.87% Return on Equity-101.78% Return on Assets-83.90% Debt Debt-to-Equity RatioN/A Current Ratio10.32 Quick Ratio10.32 Sales & Book Value Annual Sales$130,000.00 Price / Sales369.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book4.64Miscellaneous Outstanding Shares28,800,000Free Float26,240,000Market Cap$48.10 million OptionableOptionable Beta1.68 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Miranda J. Toledano M.B.A. (Age 47)CEO & Director Comp: $412.5kDr. Hillel Galitzer M.B.A. (Age 46)Ph.D., Chief Operating Officer Comp: $387kMs. Dana Yaacov-Garbeli CPA (Age 41)Chief Financial Officer Dr. Arthur C. Santora II (Age 73)M.D., Ph.D., Chief Medical Officer Comp: $355kKey CompetitorsCandel TherapeuticsNASDAQ:CADLEstrella ImmunopharmaNASDAQ:ESLAPluriNASDAQ:PLURNKGen BiotechNYSE:NKGNProtara TherapeuticsNASDAQ:TARAView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 100 shares on 2/2/2024Ownership: 0.000%Haya TaitelBought 9,500 shares on 1/12/2024Total: $9,405.00 ($0.99/share)Haya TaitelBought 7,615 shares on 1/10/2024Total: $5,863.55 ($0.77/share)Miranda Jayne ToledanoBought 23,952 shares on 12/22/2023Total: $17,005.92 ($0.71/share)Sean EllisBought 40,000 shares on 8/21/2023Total: $24,000.00 ($0.60/share)View All Insider TransactionsView All Institutional Transactions ENTX Stock Analysis - Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks. What is Entera Bio's stock price target for 2024? 1 analysts have issued twelve-month price targets for Entera Bio's stock. Their ENTX share price targets range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 498.8% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts. How have ENTX shares performed in 2024? Entera Bio's stock was trading at $0.60 on January 1st, 2024. Since then, ENTX shares have increased by 178.3% and is now trading at $1.67. View the best growth stocks for 2024 here. Are investors shorting Entera Bio? Entera Bio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,100 shares, an increase of 523.1% from the February 29th total of 1,300 shares. Based on an average daily volume of 147,000 shares, the short-interest ratio is presently 0.1 days. View Entera Bio's Short Interest. When is Entera Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ENTX earnings forecast. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The company earned $0.14 million during the quarter. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager. Who are Entera Bio's major shareholders? Entera Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Haya Taitel, Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.